Clinical Trial Update: N-acetylcysteine (NAC) for Improving Cognitive Dysfunction in Schizophrenia [Phase 1]

View source ↗

Summary

Phase 1 clinical trial evaluating N-acetylcysteine (NAC) for improving cognitive dysfunction in schizophrenia has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Schizophrenia

Drugs mentioned

• N-acetylcysteine (N-acetylcysteine)

Snippet

Sponsor: VA Greater Los Angeles Healthcare System | Conditions: Schizophrenia | Phase 1 | Status: COMPLETED